title: Inactivation of viruses in therapeutic products derived from human plasma.
abstract: Alpha-1-proteinase inhibitor concentrates have been prepared from pooled human plasma for therapeutic applications. Pasteurization (60 degrees C, 10 hours) conditions have been defined to reduce risks of transmission of viral agents without significant loss of biologic activity of the purified product. Human clinical data collected to date support the model virus inactivation studies regarding viral safety.
authors.affiliation: Cutter Biological of Miles Inc., Berkeley, California 94701.
authors.forename: G
authors.initials: G
authors.lastname: Mitra
authors.forename: M B
authors.initials: MB
authors.lastname: Dobkin
authors.forename: R E
authors.initials: RE
authors.lastname: Louie
authors.forename: M M
authors.initials: MM
authors.lastname: Mozen
mesh_terms: D001798:Blood Proteins / Q000008:administration & dosage*; D004340:Drug Contamination / Q000517:prevention & control*; D006678:HIV; D006358:Hot Temperature; D014790:Visna-maedi virus; D000515:alpha 1-Antitrypsin
chemical_list: D001798:Blood Proteins; D000515:alpha 1-Antitrypsin